ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "metabolomics"

  • Abstract Number: 0925 • ACR Convergence 2025

    Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis

    Megan M. Hanlon1, Catherine Manning1, Kevin Wei1, Ursula Fearon2 and Ellen M. Gravallese3, 1Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 2Trinity College Dublin, Dublin, Dublin, Ireland, 3Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Synovial tissue macrophages (STMs) represent a mixed population of cells contributing to the pathogenesis of rheumatoid arthritis (RA). We identified an enrichment of Secreted…
  • Abstract Number: 0901 • ACR Convergence 2025

    Data-Driven Metabolomics Identifies Diagnostic Signatures and Patient Subgroups in Systemic Autoimmune Disorders

    Chary López pedrera1, Antonio Perez-Campoamor2, Gema Dolores García-Delgado3, Beatriz Vellón-García4, Adrián Llamas Urbano5, Laura Romero Zurita6, Pedro Ortiz Buitrago7, Christian Merlo8, Maria del carmen abalos-aguilera8, Nuria Barbarroja9, Verónica Bolón-Canedo10, MARIA ANGELES AGUIRRE ZAMORANO11, Rafaela Ortega-Castro12, Jerusalén Calvo13, Lourdes Ladehesa14, Marta Alarcon-Riquelme15, Alejandro Escudero-contreras8 and Carlos Pérez Sánchez16, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2STARTQUAKE S.L., Gijón, Spain/Research Center on Information and Communication Technologies (CITIC), University of A Coruña, A Coruña, Spain, Gijón, Spain, 3Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, 4Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, 5Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, 6Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Córdoba, Spain, 7Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, 8Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 10Research Center on Information and Communication Technologies (CITIC), University of A Coruña, A Coruña, Spain, A coruña, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 12Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 13IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 14IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 15Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 16Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: This study aims to characterize the metabolomic fingerprint of several systemic autoimmune diseases (SADs) and apply machine learning (ML) techniques to identify disease-specific biomarkers…
  • Abstract Number: 0700 • ACR Convergence 2025

    Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension

    Martina Iacubino1, Lorenzo Rocco2, Marco Vicenzi2, Chiara Bellocchi2, Marta Mozzo3, adriana severino3, Monica Caronni3, Alessandro Santaniello3, Gaia montanelli3, Barbara Vigone3, LIam Grimmett4, Matt Kerr4 and Lorenzo Beretta5, 1UNIMI, Milano, Milan, Italy, 2University of Milan, Milan, Italy, 3Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 4Owlstone Medical, Cambridge, United Kingdom, 5Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Accurate and early diagnosis of SSc-PAH…
  • Abstract Number: 0871 • ACR Convergence 2025

    The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes

    Vanya Sofia Villa Soto1, Diego Orellana2, Erin Reilly3, Chloe Heath2, Alexandra Degraeve2, Mohana Mukherjee2, darren Dumlao2, Rebecca Blank4, steven Yu2, Noah Perlmutter2, Judith Ashouri2, Jose Scher5, andrew Patterson3, Peter Turnbaugh2 and Renuka Nayak6, 1University of California, San Francisco, San Francics, CA, 2University of California, San Francisco, San Francisco, CA, 3Pennsylvania State University, University Park, PA, 4NYU Langone Health, New York, NY, 5New York University School of Medicine, New York, NY, 6University of California, San Francisco (UCSF), San Francisco, CA

    Background/Purpose: Despite advances in targeted therapeutics, methotrexate (MTX) remains the first-line therapy in the treatment of rheumatoid arthritis (RA) and other inflammatory arthritides. However, more…
  • Abstract Number: 0324 • ACR Convergence 2025

    Bile Acids Metabolism in Symptomatic Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study and Genetics of OA Consortium

    Jiatian Li1, Jing Ye1, Tuo Yang1, david Hunter2, Weiya Zhang3, Michael Doherty3, Yuqing Zhang4, Zidan Yang1, Hui Li1, Yilun Wang1, Dongxing Xie1, Ziying Wu5, Wei Li1, Zeqin Wen1, Changjun Li1, Chao Zeng1, Guanghua Lei1 and Jie Wei1, 1Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), 2Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 3School of Medicine, University of Nottingham, Nottingham, United Kingdom, 4Massachusetts General Hospital, Quincy, MA, 5Xiangya Hospital, Central South University, Chang Sha, China (People's Republic)

    Background/Purpose: Although gut microbiome dysbiosis has been implicated in symptomatic hand OA (SHOA), the potential contribution of bile acids (BAs), key metabolites in host-microbiota interactions,…
  • Abstract Number: 0322 • ACR Convergence 2025

    Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative

    Jeffrey Driban1, Shike Xu2, Timothy McAlington3, John Haran4, Julieann Patarini4 and Bing Lu5, 1University of Massachusetts Chan Medical School, Marlborough, NH, 2University of Connecticut Health Center, Farmington, CT, 3UMass Chan School of Medicine, Arlington, MA, 4UMass Chan Medical School, Worcester, MA, 5UConn Health Center, Newton, MA

    Background/Purpose: Numerous cross-sectional and animal studies have linked an altered gut microbiome to osteoarthritis (OA). Human studies are needed to explore the association between the…
  • Abstract Number: 0318 • ACR Convergence 2025

    Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study

    Cheng Li1, Jing wu2, Yuqing Zhang3, Hongyi He4, Ying Hu5, Jie Wei6, Guanghua Lei6 and Chao Zeng6, 1Xiangya Hospital, Changsha, China (People's Republic), 2Xiangya Hospital, chagnsha, Hunan, China (People's Republic), 3Massachusetts General Hospital, Quincy, MA, 4Xiangya Hospital Central South University, Changsha, China (People's Republic), 5Xiangya School of Public Health Central South University, changsha, China (People's Republic), 6Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)

    Background/Purpose: Lipoprotein subclasses play diverse roles in health and disease. Although lipoproteins have been implicated in knee osteoarthritis (KOA), the relationship between lipoprotein subclasses and…
  • Abstract Number: 2599 • ACR Convergence 2025

    Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites

    Beatriz Vellón-García1, Sagrario Corrales-Díaz-Flores2, MARIA ANGELES AGUIRRE ZAMORANO3, Ismael Sanchez-Pareja3, Laura muñoz-Barrera3, Tomás Cerdó3, Pedro Seguí-Azpilcueta4, Christian Merlo2, Maria del carmen abalos-aguilera2, Nuria Barbarroja5, Rafaela Ortega-Castro6, José-Antonio Gonzalez-Reyes7, Alejandro Escudero-contreras2, Chary López pedrera8, Jose manuel Villalba9 and Carlos Pérez Sánchez10, 1Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, 2Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 4Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, 5Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 7Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA3)., Cordoba, Spain, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 9Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: This study aims to:1- Characterize the circulating metabolomic signature in APS patients; 2- Investigate the role of hepatic involvement in the pathophysiology of APS;…
  • Abstract Number: 0087 • ACR Convergence 2025

    Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms

    Laura muñoz-Barrera1, Carlos Pérez Sánchez2, Rafaela Ortega-Castro3, Sagrario Corrales1, Tomás Cerdó1, Ismael Sanchez-Pareja1, Pilar Font4, Jerusalen Calvo Gutierrez5, M Carmen Abalos-Aguilera6, Desiree Ruiz-Vilchez7, Pedro Seguí-Azpilcueta8, Christian Merlo-Ruiz6, Jose Javier Pérez Venegas9, DOLORES RUIZ MONTESINOS10, Carmen Maria Romero Barco11, Antonio Fernández-Nebro12, Natalia Mena Vázquez13, FRANCISCO JAVIER GODOY NAVARRETE14, ALBA MARIA CABEZAS LUCENA15, MARIA ANGELES AGUIRRE ZAMORANO1, Nuria Barbarroja16, Alejandro Escudero17 and Chary López pedrera18, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 4Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 5Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 7Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, 8Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, 9Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, 10Virgen Macarena University Hospital, Sevilla, Spain, Cordoba, 11Virgen de la Victoria Hospital Malaga, Spain, Malaga, Spain, 12Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, 13Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, 14Jaen University Hospital, Spain, Jaen, Spain, 15Jaen University Hospital, Spain, Jaen, 16Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 17Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, 18Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain

    Background/Purpose: Lipid metabolism plays a key role in immune cell plasticity, influencing activation, differentiation and function. Inflammation alters this metabolism, contributing to disease progression. Extensive…
  • Abstract Number: 2589 • ACR Convergence 2025

    Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome

    Yuanpiao Ni1, Fanxin Zeng2, Yufeng Qing3 and Quanbo Zhang3, 1Affiliated Hospital Of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic), 2Dazhou Central Hospital, Dazhou, Sichuan, China (People's Republic), 3The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China (People's Republic)

    Background/Purpose: Gout is a metabolic disorder driven by abnormalities in urate metabolism and chronic inflammation. Recent studies suggest that gout is not limited to joint…
  • Abstract Number: 2303 • ACR Convergence 2025

    Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial

    Ruiling Feng, Bo Huang and Yuebo Jin, Peking University People’s Hospital, Beijing, China (People's Republic)

    Background/Purpose: Low-dose interleukin 2 (Ld-IL2) is increasingly being explored as an immune-modulating treatment for autoimmune diseases which mainly affect T cell subsets. This study investigates…
  • Abstract Number: 2061 • ACR Convergence 2025

    Tryptophan Metabolism Alteration Is Associated With Rapidly Progressive Interstitial Lung Disease Of Anti-MDA5+ Dermatomyositis

    Hongjiang liu, Yixue Guo, Xinhua dai, beibei cui, bo chen, changpei li, shuyi liao, Junlong zhang and Qibing Xie, West China Hospital, Sichuan University, Chengdu, China (People's Republic)

    Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) is an autoimmune condition associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. Metabolic disturbances…
  • Abstract Number: 1851 • ACR Convergence 2025

    Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage

    Chary López pedrera1, Laurel Woodridge2, Sagrario Corrales3, Juan Rafael Muñoz-Castañeda4, Ana Isabel Torralbo4, Anisur Rahman5, Filipa Farinha2, Rafaela Ortega-Castro6, Pedro Seguí-Azpilcueta7, Ismael Sanchez-Pareja3, Laura muñoz-Barrera3, Christian Merlo-Ruiz8, Desiree Ruiz-Vilchez9, M Carmen Abalos-Aguilera8, Pilar Font10, Nuria Barbarroja11, Marta Alarcon-Riquelme12, Alejandro Escudero Contreras13, MARIA ANGELES AGUIRRE ZAMORANO3, Carlos Pérez Sánchez14, Elizabeth C Jury5 and Tomás Cerdó3, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 4IMIBIC/Hospital Reina Sofía/University of Córdoba, Córdoba, Spain, 5University College London, London, United Kingdom, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 7Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 9Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 12Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 13IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 14Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe…
  • Abstract Number: 1841 • ACR Convergence 2025

    Differential metabolomic signatures along lupus nephritis spectrum

    Mariana Jiménez Tirado1, karina santana2, Jiram Torres Ruiz3, Jennifer Tiaré Balderas Miranda4, Diana Gómez-Martín5, José Carlos Páez Franco6, Nancy R Mejía Domínguez7, Hilda Sánchez Vidal6 and Imelda Cecilia Zarzoza Mendoza8, 1Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 2INCMNSZ, Ciudad de México, Federal District, Mexico, 3INCMNSZ, Mexico, Federal District, Mexico, 4Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 5INCMNSZ, Mexico city, Federal District, Mexico, 6Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Distrito Federal, Mexico, 7Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 8Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…
  • Abstract Number: 1840 • ACR Convergence 2025

    Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity

    Lorenzo Beretta1, Martina Iacubino2, Lorenzo Rocco3, Alexandre Voskuijl4, Marta Alarcon-Riquelme5, Guillermo Barturen6, LIam Grimmett7, Matt Kerr7, Chiara Bellocchi3, Barbara Vigone8, Alessandro Santaniello8 and Ioannis Parodis9, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, 2UNIMI, Milano, Milan, Italy, 3University of Milan, Milan, Italy, 4Amsterdam University Medical Center, Amsterdam, Netherlands, 5Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 6Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 7Owlstone Medical, Cambridge, United Kingdom, 8Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 9Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden

    Background/Purpose: 3TR (taxonomy, treatment, targets and remission) aims to provide insights into the mechanisms of response and non-response to treatment in systemic autoimmune diseases, including…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology